Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Attenuating Ischemia Reperfusion Injury in Kidney Transplant
NCT01149993Phase 4Withdrawn
- Sponsor
- Georgetown University
- Start
- Jun 2010
- Primary completion
- Jun 2012
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
Phase 4, randomised, open-label trial of mycophenolate sodium and antithymocyte globulin in ischemia-reperfusion injury (IRI) (3 arms), sponsored by Georgetown University. Primary endpoint: reduction in ischemia reperfusion injury at 1 year. Planned start Jun 2010; status: withdrawn.
02
Drugs
mycophenolate sodiumantithymocyte globulin
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01149993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01149993.